3.6800
-0.3500
(-8.68%)
At close: January 10 at 4:00:01 PM EST
3.5600
-0.12
(-3.26%)
After hours: 7:57:26 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
--
--
8,094.0000
13,620.0000
--
Operating Expense
112,097.0000
104,315.0000
107,368.0000
85,874.0000
86,462.0000
Operating Income
-112,097.0000
-104,315.0000
-99,274.0000
-72,254.0000
-86,462.0000
Net Non Operating Interest Income Expense
8,938.0000
7,142.0000
2,616.0000
64.0000
115.0000
Other Income Expense
723.0000
1,158.0000
10,677.0000
2.0000
-1,943.0000
Pretax Income
-102,436.0000
-96,015.0000
-85,981.0000
-72,188.0000
-88,290.0000
Net Income Common Stockholders
-102,436.0000
-96,015.0000
-85,981.0000
-72,188.0000
-88,290.0000
Diluted NI Available to Com Stockholders
-102,436.0000
-96,015.0000
-85,981.0000
-72,188.0000
-88,290.0000
Basic EPS
-3.04
-4.83
-10.10
-10.14
-25.50
Diluted EPS
-3.04
-4.83
-10.10
-10.14
-25.50
Basic Average Shares
35,195.3540
19,884.0070
8,512.0890
7,118.0240
3,462.4750
Diluted Average Shares
35,195.3540
19,884.0070
8,512.0890
7,118.0240
3,462.4750
Total Operating Income as Reported
-112,097.0000
-104,252.0000
-106,452.0000
-72,254.0000
-88,406.0000
Total Expenses
112,097.0000
104,315.0000
107,368.0000
85,874.0000
86,462.0000
Net Income from Continuing & Discontinued Operation
-102,436.0000
-96,015.0000
-85,981.0000
-72,188.0000
-88,290.0000
Normalized Income
-102,436.0000
-96,078.0000
-97,039.0000
-72,188.0000
-86,346.0000
Interest Income
8,864.0000
7,142.0000
2,616.0000
64.0000
115.0000
Net Interest Income
8,938.0000
7,142.0000
2,616.0000
64.0000
115.0000
EBIT
-110,810.0000
-104,315.0000
-99,274.0000
-72,254.0000
-86,462.0000
EBITDA
-108,630.0000
-101,734.0000
-96,866.0000
-69,290.0000
-82,540.0000
Reconciled Depreciation
2,180.0000
2,581.0000
2,408.0000
2,964.0000
3,922.0000
Net Income from Continuing Operation Net Minority Interest
-102,436.0000
-96,015.0000
-85,981.0000
-72,188.0000
-88,290.0000
Total Unusual Items Excluding Goodwill
--
63.0000
11,058.0000
--
-1,944.0000
Total Unusual Items
--
63.0000
11,058.0000
--
-1,944.0000
Normalized EBITDA
-108,630.0000
-101,797.0000
-107,924.0000
-69,290.0000
-80,596.0000
12/31/2020 - 1/26/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
DTIL Precision BioSciences, Inc.
5.70
+26.67%
MRSN Mersana Therapeutics, Inc.
0.7200
-44.62%
DYN Dyne Therapeutics, Inc.
15.87
-31.15%
IMRX Immuneering Corporation
2.0700
+3.50%
STOK Stoke Therapeutics, Inc.
9.00
+0.45%
IPSC Century Therapeutics, Inc.
0.9900
-7.48%
NLSP NLS Pharmaceutics AG
2.3200
-3.73%
GDTC CytoMed Therapeutics Limited
2.7600
+20.52%
DBVT DBV Technologies S.A.
4.9700
+29.77%
SAGE Sage Therapeutics, Inc.
5.55
-5.13%